Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIRECT trial of neoadjuvant durvalumab with adaptive low-dose radiotherapy in early-stage NSCLC
NL-OMON60945Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety, Major pathological response and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60945.